Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US-Reference-Cited by-同舟云学术

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US

Published:2022-08-05 Issue:9 Volume:13 Page:1659-1670
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Shao Hui,Alsaleh Abdul Jabbar Omar,Dex Terry,Lew Elisheva,Fonseca Vivian

Funder

Sanofi, France

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13300-022-01300-5.pdf

Reference33 articles.

1. Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care. 2018;41:963–70.

2. Centers for Disease Control and Prevention. Type 2 diabetes. https://www.cdc.gov/diabetes/basics/type2.html. Accessed 1 July 2022.

3. Centers for Disease Control and Prevention. Prevalence of both diagnosed and undiagnosed diabetes. https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-undiagnosed-diabetes.html. Accessed 8 Oct 2021.

4. IDF Diabetes Atlas. Key global findings 2021. https://diabetesatlas.org. Accessed 5 Dec 2021.

5. Leung E, Wongrakpanich S, Munshi MN. Diabetes management in the elderly. Diabetes Spectrum. 2018;31:245–53.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. Cost‐effectiveness analysis of a digital diabetes‐prevention programme versus an in‐person diabetes‐prevention programme in people with prediabetes in the United States;Diabetes, Obesity and Metabolism;2024-07-26

3. Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study;Advances in Therapy;2024-01-19

4. Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus;Diabetes Therapy;2023-10-06

5. A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China;Clinical Drug Investigation;2023-03-21